 |
 |
TABLE OF CONTENTS |
March 2014 Volume 32, Issue 3 |
 |  |  |
 | Editorial News Correction Bioentrepreneur Opinion and Comment Features News and Views Computational Biology Research Careers and Recruitment
| |
 |
|
 |
 |
| Advertisement |
 |
|
 |
| |
| Advertisement |
 |
 The Structural Genomics Consortium (SGC), Natureconferences, and the São Paulo Research Foundation are pleased to present: Chemical Probe-based Open Science: Uncovering New Human and Plant Biology April 28-29, 2014 Faculdade de Ciências Médicas, State University of Campinas (UNICAMP), Brazil Click here for more information or to register for this conference today! | | | |
 |
| |
Editorial | Top |
 |
 |
 |
Is this really the RNAissance? p201 doi:10.1038/nbt.2853 Renewed investor interest in RNA interference (RNAi) is enabling pioneering companies to forge ahead in the clinic. Does this signify a renaissance in RNAi therapy?
|
 |
News | Top |
 |
 |
 |
Markets, venture investors and big pharma interest in RNAi soars pp203 - 204 Aaron Bouchie doi:10.1038/nbt0314-203
|
 |
 |
 |
First integrin inhibitor since Tysabri nears approval for IBD pp205 - 207 Cormac Sheridan doi:10.1038/nbt0314-205
|
 |
 |
 |
GSK picks six cancer research centers p206 Suzanne Elvidge doi:10.1038/nbt0314-206
|
 |
 |
 |
Intercept price quadruples in a day p207 Brian Orelli doi:10.1038/nbt0314-207
|
 |
 |
 |
Amgen and Regeneron push for a genetic renaissance in drug discovery pp208 - 209 Michael Eisenstein doi:10.1038/nbt0314-208
|
 |
 |
 |
BMS sells diabetes business p209 Asher Mullard doi:10.1038/nbt0314-209
|
 |
 |
 |
First recombinant Factor XIII approved p210 Emma Dorey doi:10.1038/nbt0314-210a
|
 |
 |
 |
Around the world in a month p210 doi:10.1038/nbt0314-210b
|
 |
 |
 |
Myriad diversifies, fights rearguard action on patents p211 Malorye Allison doi:10.1038/nbt0314-211a
|
 |
 |
 |
Microbes unite Novozymes and Monsanto p211 Jeffrey L Fox doi:10.1038/nbt0314-211b
|
 |
 |
 |
Roche bets on alpha-synuclein for Parkinson's p212 Gunjan Sinha doi:10.1038/nbt0314-212a
|
 |
Correction | Top |
 |
 |
 |
Corrections p212 doi:10.1038/nbt0314-212b
|
 |
Bioentrepreneur | Top |
 |
 |
 |
| Building a business |
 |
 |
 |
Acquiring orphans pp213 - 216 Rogier Rooswinkel, Geert-Jan Mulder and Sander van Deventer doi:10.1038/nbt.2836
|
 |
 |
 |
| SciCafé |
 |
 |
 |
Startups on the menu: Circuit Therapeutics p216 doi:10.1038/nbt.2837
|
 |
Opinion and Comment | Top |
 |
 |
 |
| Correspondence |
 |
 |
 |
Interactive visualization and analysis of large-scale sequencing datasets using ZENBU pp217 - 219 Jessica Severin, Marina Lizio, Jayson Harshbarger, Hideya Kawaji, Carsten O Daub et al. doi:10.1038/nbt.2840
|
 |
 |
 |
OpenSWATH enables automated, targeted analysis of data-independent acquisition MS data pp219 - 223 Hannes L Rost, George Rosenberger, Pedro Navarro, Ludovic Gillet, Sasa M Miladinovic et al. doi:10.1038/nbt.2841
|
 |
 |
 |
ProteomeXchange provides globally coordinated proteomics data submission and dissemination pp223 - 226 Juan A Vizcaino, Eric W Deutsch, Rui Wang, Attila Csordas, Florian Reisinger et al. doi:10.1038/nbt.2839
|
 |
 |
 |
| Commentary |
 |
 |
 |
From the analyst's couch: The outlook for biotech exits pp227 - 228 Annette Grimaldi doi:10.1038/nbt.2852 The spectacular performance of biopharma companies in the public markets last year has carried over into optimism for early 2014. Will the boom continue?
|
 |
Features | Top |
 |
 |
 |
Nature Biotechnology's academic spinouts of 2013 pp229 - 238 Aaron Bouchie, Malorye Allison, Sarah Webb and Laura DeFrancesco doi:10.1038/nbt.2846 Ventures focusing on gene therapy, adoptive T-cell therapy, protein homeostasis and the microbiome are among those selected by the editors in 2013's crop of startups.
|
 |
 |
 |
| Patents |
 |
 |
 |
Recent patent applications in chimeric antigen receptors p239 doi:10.1038/nbt.2854
|
 |
News and Views | Top |
 |
 |
 |
|
 |
Computational Biology | Top |
 |
 |
 |
| Analysis |
 |
 |
 |
Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls pp246 - 251 Justin M Zook, Brad Chapman, Jason Wang, David Mittelman, Oliver Hofmann et al. doi:10.1038/nbt.2835 Zook et al. describe methods for integrating genome variants from five sequencing technologies to characterize the first benchmark sample that can be used to understand accuracy of human whole-genome and targeted sequencing.
|
 |
Research | Top |
 |
 |
 |
| Perspective |
 |
 |
 |
Mesenchymal stem cells: immune evasive, not immune privileged pp252 - 260 James A Ankrum, Joon Faii Ong and Jeffrey M Karp doi:10.1038/nbt.2816
|
 |
 |
 |
| Articles |
 |
 |
 |
Whole-genome haplotyping using long reads and statistical methods pp261 - 266 Volodymyr Kuleshov, Dan Xie, Rui Chen, Dmitry Pushkarev, Zhihai Ma et al. doi:10.1038/nbt.2833 Haplotyping of human genomes is improved by augmenting experimental dilution-based haplotyping with statistical analyses, a strategy known until now only as 'Moleculo.'
|
 |
 |
 |
Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library pp267 - 273 Hiroko Koike-Yusa, Yilong Li, E-Pien Tan, Martin Del Castillo Velasco-Herrera and Kosuke Yusa doi:10.1038/nbt.2800 CRISPR-Cas9 genome editing technology is used for genome-wide genetic screens in mouse embryonic stem cells.
|
 |
 |
 |
| Letters |
 |
 |
 |
Virally mediated optogenetic excitation and inhibition of pain in freely moving nontransgenic mice pp274 - 278 Shrivats Mohan Iyer, Kate L Montgomery, Chris Towne, Soo Yeun Lee, Charu Ramakrishnan et al. doi:10.1038/nbt.2834 Viral delivery of opsins to peripheral nociceptors allows optogenetic stimulation and inhibition of pain in non-transgenic freely moving mice.
See also: News and Views by Browne & Woolf
|
 |
 |
 |
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs pp279 - 284 Yanfang Fu, Jeffry D Sander, Deepak Reyon, Vincent M Cascio and J Keith Joung doi:10.1038/nbt.2808 Guide RNAs with shorter regions of complementarity to target sites reduce off-target effects.
|
 |
 |
 |
| Resources |
 |
 |
 |
The binary protein-protein interaction landscape of Escherichia coli pp285 - 290 Seesandra V Rajagopala, Patricia Sikorski, Ashwani Kumar, Roberto Mosca, James Vlasblom et al. doi:10.1038/nbt.2831 Yeast-two hybrid screening of E. coli proteins and integration with protein structure and genetic interaction data provides an extensive interactome resource.
See also: News and Views by Stelzl
|
 |
 |
 |
| Corrigenda |
 |
 |
 |
Corrigendum: Reproducibility of high-throughput mRNA and small RNA sequencing across laboratories p291 Peter A C 't Hoen, Marc R Friedlander, Jonas Almlof, Michael Sammeth, Irina Pulyakhina et al. doi:10.1038/nbt0314-291a
|
 |
 |
 |
| Errata |
 |
 |
 |
Erratum: A single-molecule long-read survey of the human transcriptome p291 Donald Sharon, Hagen Tilgner, Fabian Grubert and Michael Snyder doi:10.1038/nbt0314-291b
|
 |
 |
 |
Erratum: Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure p291 Suraj J Patel, Jack M Milwid, Kevin R King, Stefan Bohr, Arvin Iracheta-Velle et al. doi:10.1038/nbt0314-291c
|
 |
 |
 |
| Corrigendum |
 |
 |
 |
Corrigendum: In search of dry powder p291 Jonathan Behr and Phil Murray doi:10.1038/nbt0314-291d
|
 |
Careers and Recruitment | Top |
 |
 |
 |
Profiling the reform-era life sciences executive pp292 - 293 John McLean doi:10.1038/nbt.2847 Healthcare's reform era is here, requiring executives in the life sciences industry to think differently about their skill sets and capabilities.
|
 |
 |
 |
| People |
 |
 |
 |
People p294 doi:10.1038/nbt.2855
|
 |
| Advertisement |
 |
nature.com webcasts
Macmillan Science Communication presents a custom webcast: Realizing the promise of genomics through rapid innovation in biological analysis and interpretation.
Thursday 13 March at 8am PDT/11am EDT/3pm GMT/4pm CET
Register for the free webcast followed by a live Q & A session
Sponsored by: | | | |
 |
| |
 |  |  |  |  |  | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com |  |  |  |  |  |
|
 |
No comments:
Post a Comment